La catena delle opzioni mostra i dati chiave delle opzioni azionarie di LENZ Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per LENZ Therapeutics..

LENZ Therapeutics (NASDAQ:LENZ) Azioni, Catena delle Opzioni

LENZ Therapeutics

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

LENZ Therapeutics Inc

LENZING AG U/ADR by Lenzing AG

Lenzing AG

WIIM

QNTM

Quantum BioPharma shares are trading higher after the company announced legal teams have been assembled to pursue the recovery of all losses and damages.

RBC Capital analyst Christopher Dendrinos maintains GE Vernova (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEV#NYSE">GEV</a>) with a Outperform and raises the price target from $285 to $376.

News

Price Target

Analyst Ratings

RBC Capital Maintains Outperform on GE Vernova, Raises Price Target to $376

UPXI

Upexi shares are trading lower. The company filed litigation in Nevada in determining manipulation of fractional share roundups during its reverse stock split.

JMP Securities analyst Andrew Boone maintains Reddit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDDT#NYSE">RDDT</a>) with a Market Outperform and raises the price target from $118 to $160.

RDDT

JMP Securities Maintains Market Outperform on Reddit, Raises Price Target to $160

Vast Renewables Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares traded higher after the company signed <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g42161696/vast-receives-30m-from-australian-renewable-energy-agency-for-green-technology-to-decarbonise-aust" rel="noreferrer noopener">an updated funding agreement</a>.
The agreement will give access up to $30 million of its $65 million grant from the Australian Renewable Energy Agency.
The funding will support Vast&#8217;s green technology manufacturing and project development, enabling the deployment of its next-generation concentrated solar thermal power (CSP) solution to provide clean, dispatchable power and heat.
Vast has developed next-generation proprietary CSP technology, offering superior performance at lower cost and risk.
The company has a global project pipeline aimed at decarbonizing electricity generation and powering green methanol and sustainable aviation fuel production.
Proven at its pilot project in New South Wales, Vast&#8217;s technology is set for utility-scale deployment at Vast Solar 1 (VS1), a 30MW power plant with 8 hours of storage in South Australia&#8217;s Port Augusta Green Energy Hub.
The Port Augusta CSP project will generate clean, dispatchable electricity for the National Electricity Market and power Solar Methanol 1 (SM1), a world-first green methanol production facility.
Vast&#8217;s Australian-made CSP technology, produced at its Queensland facility, will benefit from $30 million in funding from ARENA.
This will support the scaling of manufacturing for VS1 and future projects, as well as final development activities ahead of the Final Investment Decision in early 2025.
The funding is expected to create green manufacturing, construction, and long-term operations jobs.
Construction of VS1 is expected to start in the second quarter of 2025, with capital expenditures estimated between A$360 million and A$390 million.
CEO Craig Wood emphasized that the Australian Government support positions Vast to lead a domestic CSP industry and expand its global project pipeline.
Price Action: VSTE shares are up 30.4% at $2.151 at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42165679" target="_blank" rel="noreferrer noopener">Nio Analyst Sees Tougher Path To Profitability, Downgrades EV Maker To Sell: What You Need To Know</a></li>
</ul>
Image via Unsplash.

Equities

Small Cap

Movers

VSTE

Vast Renewables Powers Up: $30M Funding Fuels Australia's Next-Gen Solar And Methanol Breakthrough

Wells Fargo analyst Zachary Fadem maintains Tractor Supply (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSCO#NASDAQ">TSCO</a>) with a Overweight and lowers the price target from $325 to $320.

TSCO

Wells Fargo Maintains Overweight on Tractor Supply, Lowers Price Target to $320

Trading Ideas

SMTK

SmartKem Shares Resume Trade Then Again Halt On Circuit Breaker To The Downside, Stock Now Up 21.9%

BMO Capital analyst Rufus Hone downgrades Block (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>) from Outperform to Market Perform and raises the price target from $94 to $100.

Downgrades

BMO Capital Downgrades Block to Market Perform, Raises Price Target to $100

Quantum BioPharma Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#NASDAQ">QNTM</a>)(CSE:<a class="ticker" href="https://www.benzinga.com/stock/QNTM#CSE">QNTM</a>)(FRA:0K91) (the "Company") formerly named FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>)(CSE:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#CSE">HUGE</a>) is pleased to follow up on recent events concerning the complaint filed by the Company in the United States courts, that alleges that CIBC World Markets, RBC Dominion Securities and others (the "Defendants") engaged in market manipulation in the share price of the Company. The Company, as well as its shareholders, have suffered financial and emotional losses resulting from this alleged manipulation. We are determined to right this wrong by the Defendants and reverse the Company losses and claim punitive damages to the extent determined by the courts. As a result, prominent legal teams have been assembled to pursue the recovery of all losses and damages impacting our Company. The law firms have agreed to be compensated without cost to the Company but solely on a contingency basis, meaning that the Company will not be billed for legal costs in this matter. The Company itself is seeking damages of more than US$700M we believe it has suffered. The shareholders can find updated information about the case on the <a href="https://stats.nwe.io/x/html?final=aHR0cHM6Ly93d3cucXVhbnR1bWJpb3BoYXJtYS5jb20vcXVhbnR1bS1iaW9waGFybWEtdnMtYmFua3M&amp;sig=5qokejQshKBtsyGPvETI3Dajx81D1ik76d53wt2_oHIhWuBBsy7ShTs5WoWCxoDKswAzLDh_haIgDwdUYAVTNw&amp;hit%2Csum=WyI0bmM0YXEiLCI0bmM0YXIiLCI0bmM0YXMiXQ">Quantum vs Banks</a> page of our website which will be updated periodically.
Quantum Biopharma previously know as FSD Pharma and traded under the symbol HUGE is inviting and requesting shareholders to join with the company in its quest to get justice for itself and all affected shareholders, both past and current. The company strongly believes the more affected and harmed shareholders that come forward to share specific details of their losses, the stronger the case will become against the alleged perpetrators, for the vast financial harm they have caused.

Short Sellers

Legal

Management

CSE:HUGE

CSE:QNTM

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

Quantum BioPharma Invites Shareholders To The $700M+ Court Case The Company Has Filed Against CIBC, RBC, And Others For Alleged Spoofing/Stock Price Manipulation

Wells Fargo analyst Stephen Baxter maintains Universal Health Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) with a Overweight and lowers the price target from $285 to $230.

Wells Fargo Maintains Overweight on Universal Health Servs, Lowers Price Target to $230

Agreement Expands EzFill's Operations to Four New States
Deal Expected to Close December 2
MIAMI, Nov. 25, 2024 (GLOBE NEWSWIRE) -- EzFill Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZFL#NASDAQ">EZFL</a>), a leading mobile fueling company, has signed a definitive agreement to acquire the fueling division of Yoshi, Inc. with the aim of expanding its U.S operations and presence.
Under the terms of the agreement, EzFill will acquire Yoshi Mobility's existing mobile fuel service assets and allows EzFill to begin operations in four new states: California, Tennessee, Texas, and Michigan. EzFill will integrate Yoshi's assets, operations and customers into its growing infrastructure. With this acquisition, EzFill plans to not only strengthen the company's footprint in its existing markets but also take advantage of EzFill's national customers and begin offering services to them in those markets. EzFill will immediately add diesel fueling to the services currently offered by Yoshi in those markets which the Company believes will immediately increase revenues in those areas. Additionally, EzFill hopes to initiate an aggressive national expansion plan, positioning itself as a leading player in the on-demand fueling sector.

EZFL

EzFill Signs Definitive Agreement For The Purchase Of Yoshi Mobility's Fuel Division, Agreement Expands Operations To Four New States; Deal Expected To Close December 2; No Financial Terms Disclosed

Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), the heavyweight of Big Tech, has hit a grim milestone in technical analysis: <a href="https://www.benzinga.com/topic/death-cross">a Death Cross</a>. 
With its share price slipping below key moving averages, MSFT stock has moved into bearish territory, casting doubts on its near-term prospects. Is this just a blip for the software giant, or the prelude to deeper woes?
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="490" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM.png" alt="" class="wp-image-663339" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25083136/Screenshot-2024-11-25-at-6.44.43-PM-300x234.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent112524&amp;t=be2bearmibe3na1">Chart created using Benzinga Pro</a>
<h2 class="wp-block-heading">MSFT Stock: Bearish Signals All Around</h2>
At $418.19, MSFT stock price trails its 20-day, 50-day and even the 200-day simple moving averages (SMAs). Technical indicators are sounding alarms:
<ul>
<li>The 20-day SMA at $418.73, the 50-day SMA at $421.65 and the 200-day SMA at $421.81 all point to a bearish signal.</li>
<li>The eight-day SMA at $417.37, continues to be driven by bullish sentiment over the short term, driven by buying pressure.</li>
<li>The Moving Average Convergence Divergence (MACD) stands at -1.11, another red flag.</li>
<li>The Relative Strength Index (RSI) at 49.09 suggests that Microsoft isn't oversold yet but is heading toward bearish momentum.</li>
</ul>
These technical markers paint a strongly bearish picture. Yet, buying pressure persists, indicating that investors still see potential for a turnaround—a glimmer of bullish hope amidst the gloom.
Read Also: <a href="https://www.benzinga.com/24/11/42160614/microsoft-ceo-satya-nadella-calls-for-culture-change-after-security-breaches-that-led-to-voluntary-pay-cut">Satya Nadella Promises &#8216;Culture Change&#8217; After Security Lapses Return To Haunt Microsoft 20 Years After Bill Gates Launched A Similar Initiative</a>
<h2 class="wp-block-heading">The ProPublica Bombshell</h2>
Compounding Microsoft's technical woes is a ProPublica investigation that has raised ethical and legal concerns over the company&#8217;s federal contracting practices. As detailed in the <a href="https://www.propublica.org/article/microsoft-white-house-offer-cybersecurity-biden-nadella">report</a>, Microsoft's "White House Offer"—a supposedly altruistic pledge to bolster government cybersecurity—was a calculated business maneuver. 
The plan involved providing free upgrades and consulting services to federal agencies, locking them into Microsoft's ecosystem. Once the "free" period ended, agencies had little choice but to continue with costly subscriptions and Azure services, effectively squeezing out competitors.
This strategy not only strengthened Microsoft's grip on federal business but also invited scrutiny for potentially violating federal procurement and antitrust laws. Legal experts argue that the deal sidesteps open competition, raising concerns about its long-term implications for government reliance on a single vendor.
<h2 class="wp-block-heading">A Double-Edged Sword</h2>
While the technical indicators signal bearishness, the buying pressure suggests a tug-of-war between short-term skepticism and long-term optimism. Microsoft's market dominance—bolstered by its lucrative cloud business and strategic maneuvers—remains a formidable moat. 
However, the ethical controversies surrounding its federal contracts could dent investor confidence and invite regulatory headwinds.
<h2 class="wp-block-heading">The Verdict</h2>
Microsoft's Death Cross is a wake-up call for investors. With the stock under technical pressure and the ProPublica revelations casting a shadow over its business practices, the path forward is murky. 
Bulls might see this as a chance to buy on weakness, banking on Microsoft's resilience. Bears, however, have a compelling case to remain cautious as the stock navigates this precarious juncture.
For now, Microsoft's crossroads is a reminder that even the mightiest of tech giants are not immune to scrutiny—or the market's harsh judgment.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/media/24/11/42136902/microsofts-brad-smith-urges-trump-government-to-tackle-growing-cyber-threats">Microsoft&#8217;s Brad Smith Urges Trump Government to Tackle Growing Cyber Threats</a></li>
</ul>
Image: Shutterstock

Long Ideas

Technicals

Signals

Tech

MSFT

Microsoft's Death Cross: Tech Giant Faces A Double Blow With FTC Pressure

SmartKem Shares Halted On Circuit Breaker To The Downside, Stock Now Up 39.4%

<a href="https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales" title="https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales">https://www.theinformation.com/articles/apples-thin-iphone-has-no-physical-sims-that-could-dampen-china-sales</a>

AAPL

"Apple's Thin iPhone Has No Physical SIMs—That Could Dampen China Sales" - The Information

JMP Securities analyst Jordan Bender maintains MGM Resorts Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>) with a Market Outperform and lowers the price target from $54 to $50.

JMP Securities Maintains Market Outperform on MGM Resorts Intl, Lowers Price Target to $50

Macro Economic Events

Econ #s

Economics

Dallas Fed Manufacturing Business Index For November -2.7 Vs -2.4 Est.; -3.0 Prior

William Blair analyst Jeff Schmitt initiates coverage on Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Outperform rating.

Initiation

NDAQ

William Blair Initiates Coverage On Nasdaq with Outperform Rating

In the current session, the stock is trading at $116.06, after a 0.36% increase. Over the past month, Walt Disney Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) stock increased by 21.08%, and in the past year, by 25.83%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2024/1732548611_0.png" alt="Past Year Chart" />

<h3>Walt Disney P/E Ratio Analysis in Relation to Industry Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Walt Disney has a lower P/E than the aggregate P/E of 52.76 of the Entertainment industry. Ideally, one might believe that the stock might perform worse than its peers, but it's also probable that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2024/1732548611_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

Price Over Earnings Overview: Walt Disney

U.S. stocks settled higher on Friday, with the Dow Jones index closed at a fresh record level during the session. Major indices on the Wall Street recorded gains last week, with the Dow gaining around 2% and the S&amp;P 500 adding around 1.7%.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Trevor Walsh
<ul>
<li>Analyst Firm: JMP Securities</li>
<li>Ratings Accuracy: 89%</li>
<li>Latest Rating: Maintained a Market Outperform rating on Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) and raised the price target from $380 to $415 on Nov. 21. This analyst sees more than 8% increase in the stock.</li>
<li>Recent News: On Nov. 20, Palo Alto reported first-quarter revenue of $2.14 billion, beating the consensus estimate of $2.12 billion. The cybersecurity company reported quarterly earnings of $1.56 per share, beating analyst estimates of $1.48 per share, according to Benzinga Pro.</li>
</ul>
Analyst: Chris Kotowski
<ul>
<li>Analyst Firm: Oppenheimer</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Downgraded rating on JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) from Outperform to Perform on Nov. 20.</li>
<li>Recent News: On Nov. 7, J.P. Morgan Real Estate Income Trust, Inc. disclosed the acquisition of a two-site, three-building logistics and storage portfolio in Tampa and Pinellas Park, Florida, for $25.8 million, excluding closing costs.</li>
</ul>
Analyst: Andrew Kaplowitz
<ul>
<li>Analyst Firm: Citigroup</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained a Buy rating on Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) and cut the price target from $166 to $161 on Nov. 20. This analyst sees around 19% upside in the stock.</li>
<li>Recent News: On Nov. 19, the company reported fourth-quarter revenue growth of 4.4% year-over-year to $2.96 billion, beating the consensus of $2.368 billion.</li>
</ul>
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 86%</li>
<li>Latest Rating: Maintained an Equal-Weight rating on Williams-Sonoma, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) and increased the price target from $140 to $165 on Nov. 21. This analyst sees around 4% decline in the stock.</li>
<li>Recent News: On Nov. 20, Williams-Sonoma reported better-than-expected third-quarter financial results.</li>
</ul>
Analyst: Aaron Rakers
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and raised the price target from $165 to $185 on Nov. 21. This analyst sees more than 30% upside in the stock.</li>
<li>Recent News: In a recent interview, Nvidia CEO Jensen Huang shared his thoughts on the company&#8217;s focus on supply as demand remains &#8220;incredible,&#8221; a development that was a big topic in the company&#8217;s recent financial results.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42137942/jim-cramer-says-this-stock-is-a-bitcoin-play-and-he-prefers-to-own-bitcoin">Jim Cramer Says This Stock Is A Bitcoin Play And He Prefers To Own Bitcoin</a></li>
</ul>

Pre-Market Outlook

NVDA

PANW

This Analyst With 85% Accuracy Rate Sees Over 30% Upside In Nvidia - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

JMP Securities analyst Jordan Bender maintains Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) with a Market Outperform and raises the price target from $35 to $36.

GDEN

JMP Securities Maintains Market Outperform on Golden Entertainment, Raises Price Target to $36

LENZ reports positive Chinese study data for far-sightedness drug

In a report released yesterday, Marc Goodman from Leerink Partners maintained a Buy rating on LENZ Therapeutics (LENZ – Research Report). The compa...

Leerink Partners Sticks to Its Buy Rating for LENZ Therapeutics (LENZ)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
LENZ Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lenz-stock-quote/">LENZ</a>) just reported results for the first quarter of 2024.<ul><li>LENZ Therapeutics reported earnings per share of -$3.53. This was below the analyst estimate for EPS of -84 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	The post <a href="https://investorplace.com/earning-results/2024/08/lenz-stock-earnings-lenz-therapeutics-for-q1-of-2024/">LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024

LENZ Therapeutics GAAP EPS of -$0.38

LENZ Therapeutics, Inc. (LENZ) Q3 2024 Earnings Call Transcript

Leerink raised the firm's price target on Lenz Therapeutics (LENZ) to $36 from $32 and keeps an Outperform rating on the shares after the company r...

Lenz Therapeutics price target raised to $36 from $32 at Leerink

Lenz Therapeutics, Inc. (LENZ) has disclosed a new risk, in the Trade Secrets category. Lenz Therapeutics, Inc. faces significant business risks re...

Patent Challenges Threaten Lenz Therapeutics' Market Strategy and Financial Stability

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on LENZ Therapeutics (LENZ – Research Report) today and set a price target of $38....

Positive Buy Rating for LENZ Therapeutics' LNZ100 Eye Drop Amid Promising Clinical Results and Market Differentiation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
LENZ Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/lenz-stock-quote/">LENZ</a>) just reported results for the first quarter of 2024.<ul><li>LENZ Therapeutics reported earnings per share of -$3.53. This was below the analyst estimate for EPS of -84 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div>	
	The post <a href="https://investorplace.com/earning-results/2024/08/lenz-stock-earnings-lenz-therapeutics-for-q1-of-2024/">LENZ Stock Earnings: LENZ Therapeutics Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Comments

LENZ Therapeutics

LENZ Therapeutics (LENZ) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO